摘要
目的探讨孟鲁司特联合布地奈德治疗小儿哮喘的临床疗效及安全性。方法选取2016年6月—2017年6月在我院就诊的88例哮喘患儿为研究对象,按随机抽签法将患儿分为2组,每组44例。其中A组患儿单独使用布地奈德治疗,B组患儿在A组治疗基础上联合孟鲁司特,比较2组患儿的临床疗效和用药安全性。结果 A组总有效率为77.27%,明显较B组的93.18%低,差异有统计学意义(P<0.05);A组不良反应率11.36%,低于B组的13.64%低,但组间比较无统计学差异(P>0.05)。结论孟鲁司特联合布地奈德治疗小儿哮喘的疗效较单独使用布地奈德更为突出,且未明显增加不良反应,具有临床推广价值。
Objective To investigate the clinical efficacy of Montelukast Combined with budesonide in the treatment of children with asthma,and to analyze the safety of combined use of drugs.Methods88children with asthma in our hospital in June2016-2017and June were selected as the research subjects.The children were divided into2groups according to the random drawing method,44cases in each group.Group A was treated with budesonide alone,while group B was treated with montelukast on the basis of A group.The clinical efficacy and drug safety of the two groups were analyzed and compared.Results The total effective rate of group A was77.27%,which was significantly lower than that of group B,and the difference was statistically significant(P<0.05).The adverse reaction rate in group A was11.36%,and was lower than that in group B,but there was no statistical difference between groups(P>0.05).Conclusion the efficacy of Montelukast Combined with budesonide in the treatment of children asthma is more prominent than that of budesonide alone,and it has high safety and is worthy of clinical promotion.
作者
韩宝蓉
Han Baorong(The Second People's Hospital of Jiangyou City,Jiangyou,Sichuan 621701)
出处
《基层医学论坛》
2019年第1期11-13,共3页
The Medical Forum
关键词
小儿哮喘
孟鲁司特
布地奈德
疗效
安全性
Childhood asthma
Montelukast
Budesonide
Curative effect
Safety
